Mineralys Therapeutics (MLYS) Other Non Operating Income (2022 - 2026)

Mineralys Therapeutics has disclosed Other Non Operating Income across 5 years of filings, most recently posting $5000.0 for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $5000.0, up 266.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $8000.0 (up 700.0% YoY), and the FY2024 annual result was $5000.0, up 66.67% from the prior year.
• Other Non Operating Income came in at $5000.0 for Q1 2026 at Mineralys Therapeutics, up from $1000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $12000.0 in Q4 2024 to a low of -$10000.0 in Q3 2024.
• The 5-year median for Other Non Operating Income is $1000.0 (2023), against an average of $1307.7.
• Across the five-year window, Other Non Operating Income soared 1100.0% in 2024 and slumped 400.0% in 2025, its largest moves.
• Mineralys Therapeutics' Other Non Operating Income stood at $4000.0 in 2022, then slumped by 75.0% to $1000.0 in 2023, then jumped by 1100.0% to $12000.0 in 2024, then sank by 91.67% to $1000.0 in 2025, then jumped by 400.0% to $5000.0 in 2026.
• The last three Other Non Operating Income figures came in at $5000.0 (Q1 2026), $1000.0 (Q4 2025), and $4000.0 (Q3 2025), per Business Quant data.